XML 27 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation
6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
Total estimated stock-based compensation expense for employees and non-employees, related to all of the Company's stock-based awards, was comprised as follows:


Three Months Ended

Six Months Ended

June 30,

June 30,

2018

2017

2018

2017

 (in thousands)
Cost of revenue
$
313

 
$
(1
)
 
$
331

 
$
(86
)
Selling and marketing
30

 
20

 
55

 
56

Research and development
33

 
63

 
63

 
120

General and administrative
223

 
349

 
373

 
727

Total stock-based compensation
$
599

 
$
431

 
$
822

 
$
817



The following table presents the stock activity and the total number of shares available for grant as of June 30, 2018:
 
(in thousands)
Balance at December 31, 2017
387

Plan Amendment
1,500

Options granted
(445
)
Restricted Stock granted
(198
)
Forfeited/Expired shares added back
142

Balance at June 30, 2018
1,386


Stock Option Activity
 
Options Outstanding
 
Number of Shares Underlying Outstanding Options
 
Weighted-Average Exercise Price
 
Weighted-Average Remaining Contractual Term
 
Aggregate Intrinsic Value
 
 
 
 
 
 (In years)
 
 
Outstanding at December 31, 2017
1,740,103

 
$
6.20

 
6.64
 
$
6

Granted
445,195

 
3.55

 
 
 
 
Exercised
(109,681
)
 
6.69

 
 
 
 
Forfeited
(142,297
)
 
7.83

 
 
 
 
Outstanding at June 30, 2018
1,933,320

 
$
5.44

 
7.40
 
$
28,762,929

Vested and expected to vest at June 30, 2018
1,875,294

 
$
5.56

 
7.34
 
$
27,788,808

Exercisable at June 30, 2018
949,598

 
$
7.42

 
5.69
 
$
12,348,636


Stock options are time-based and the majority are exercisable within 10 years of the date of grant, but only to the extent they have vested. The options generally vest as specified in the option agreements subject to acceleration in certain circumstances. In the event participants in the 2013 Plan cease to be employed or engaged by the Company, then all of the options would be forfeited if they are not exercised within 90 days. Forfeitures on option grants are estimated at 10% for non-executives and 0% for executives based on evaluation of historical and expected future turnover. Stock-based compensation expense was recorded net of estimated forfeitures, such that expense was recorded only for those stock-based awards expected to vest. The Company reviews this assumption periodically and will adjust it if it is not representative of future forfeiture data and trends within employee types (executive vs. non-executive).
Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic value of options exercised was $1.1 million for the six months ended June 30, 2018.
The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted as of the grant date. The following are the assumptions for options granted during the six months ended June 30, 2018.
Expected term (in years)
6.1
Risk-free interest rate
2.3% - 3.0%
Expected volatility
38.2% - 39.5%
Dividend rate
0%

Each of these inputs is subjective and generally requires significant judgment to determine.
The weighted average grant date fair value of options granted during the six months ended June 30, 2018 was $1.49. The total estimated fair value of employee options vested during the six months ended June 30, 2018 was $0.4 million. As of June 30, 2018, total unrecognized compensation cost related to non-vested stock options granted to employees was $1.4 million, which is expected to be recognized over a remaining weighted average vesting period of 3.0 years.
Restricted Stock Activity
 
Shares
 
Weighted Average Grant Date Fair Value Per Share
Nonvested restricted stock at December 31, 2017
41,867

 
3.84

Granted
198,247

 
17.60

Vested
(27,978
)
 
4.02

Nonvested restricted stock at June 30, 2018
212,136

 
16.68


As of June 30, 2018, total unrecognized compensation cost related to the nonvested restricted stock awards, which will be recognized over a remaining weighted average vesting period of 3.0 years was minimal.

Stock Warrants
In connection with and as consideration for the concessions in the Amended Notes, the Company issued to SG VTB and a trust affiliated with Ronald Doornink, the Chairman of the Board, warrants to purchase an aggregate 0.4 million shares of the Company’s common stock at an exercise price of $10.16 per share. The warrants are exercisable for a period of five years beginning on the date of issuance, July 22, 2015. The exercise price and the number of purchasable shares of common stock are subject to adjustment and do not carry any voting rights or other rights as a stockholder of the Company prior to exercise.

In connection with the November Note, the Company issued warrants to purchase 0.3 million shares of the Company’s common stock at an exercise price of $8.00 per share to SG VTB. The exercise price and the number of purchasable shares of common stock are subject to standard anti-dilution adjustments and do not carry any voting rights as a stockholder of the Company prior to exercise. The warrants are exercisable for a period of ten years beginning on the date of issuance and do not entitle the holder to any voting rights or other rights as a stockholder of the Company prior to exercise.

The warrants entitle the holder to purchase a stated amount of shares of common stock at a fixed exercise price that are not puttable (either the warrant or the shares) to the Company or redeemable for cash, and as such are classified within equity. The shares issuable upon exercise of the warrants are also subject to the “demand” and “piggyback” registration rights set forth in the in the Company’s Stockholder Agreement, dated August 5, 2013, as amended July 10, 2014.